Product is being repurposed as a women’s health treatment.

Meditrina Pharmaceuticals completed a contract manufacturing agreement for drug product development and active pharmaceutical ingredient supply with a unit of Pfizer CentreSource for the company’s lead product candidate, Femathina™ (MPI-674).

Currently in Phase II trials, MPI-674, is an aromatase inhibitor that Meditrina says it is repurposing for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding.

Previous articleScientists Develop Test for Early Detection of HCC
Next articleCellCyte Forms Device Division for Stem Cell Cultivation and Replication Products